https://clarivate.com/life-sciences-healthcare/report/dlsfim0006-2025-biopharma-psoriatic-arthritis-disease-landscape-forecast-g7-2025/
Psoriatic Arthritis | Disease Landscape & Forecast | G7 | 2025 | Clarivate
The psoriatic arthritis (PsA) treatment market is experiencing significant shifts with the introduction of newer targeted therapies, such as AbbVie's Rinvoq...
psoriatic arthritisg7 2025diseaselandscapeforecast
https://clarivate.com/life-sciences-healthcare/report/dlsfop0001-2025-biopharma-age-related-macular-degeneration-disease-landscape-and-forecast-g7-2025/
Age-Related Macular Degeneration | Disease Landscape and Forecast | G7 | 2025 | Clarivate
Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula,...
macular degenerationg7 2025agerelateddisease
https://clarivate.com/life-sciences-healthcare/report/dlsfon0015-2025-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2025/
Gastroesophageal Cancer | Disease Landscape & Forecast | G7 | 2025 | Clarivate
cancer diseaseg7 2025landscapeforecastclarivate
https://oecd.ai/en/wonk/complete-haip-reporting-framework
Complete the G7 Hiroshima AI Process Reporting Framework by 15 April 2025 and join the leaders...
If your organisation develops advanced AI systems, you can help establish the standard for responsible AI governance.